Genvoya是由吉利德科学(Gilead Sciences)公司开发的四合一复方片剂,于2015年11月5日由美国FDA批准上市,并于2015年11月23日被欧盟药监局(EMEA)批准上市。该药由固定剂量的埃替格韦(elvitegravir,150 mg)、Cobicistat(150 mg)、恩曲他滨(emtricitabine,200mg)和替诺福韦艾拉酚胺富马酸盐(tenofovir alafenamide fumarate,10 mg)组成,仅需日服一次,用于从未针对艾滋病毒进行治疗或艾滋病毒处于抑制状态的12岁以上 Genvoya, a four-in-one compound tablet developed by Gilead Sciences, was approved by the FDA for marketing on November 5, 2015 and approved by the European Food and Drug Administration (EMEA) on November 23, 2015 Listing. The drug consists of a fixed dose of elvitegravir (150 mg), Cobicistat (150 mg), emtricitabine (200 mg) and tenofovir alafenamide fumarate 10 mg) on ​​a daily basis for persons over the age of 12 years who have never been treated for HIV or who have been in an HIV-suppressed condition